Current and upcoming Clinical Trials
DUE TO COVID-19 OUR TRIALS ARE CURRENTLY ONHOLD
Current trials - RECRUITING NOW
- AES - INVESTIGATIONS OF IMMUNE MECHANISMS OF THE AIRWAY EPITHELIUM. Airway epithelial cells are the building blocks that make up the surface of the airways, known as the epithelium. This study aims to investigate defence mechanisms of these airway epithelial cells from patients with airways diseases. The airway epithelium has been shown to play roles in immunity, inflammation, tissue remodelling and host defence. Patients with inflammation in their airways are more susceptible to respiratory infections than healthy individuals, with epithelial cells proven to function differently in both asthma and Chronic Obstructive Pulmonary Disease (COPD) compared to health. The airway epithelium is the first place in the airways to come into contact with inhaled bacteria. It can communicate with other cells in the airway (immune cells) to kill the bacteria and prevent infection. We are particularly interested in discovering why some patients experience prolonged infections while others don’t. In the laboratory we will isolate cells from the samples you gift, and measure their responses when we add bacteria and other stimulants.
STIFLE - Investigating Asthma inflammation in patients taking daily Asthma medication. Measurements will be performed daily by patients at home using devices which will connect to a smartphone.
- Are you aged over 18
- Have you been diagnosed with Asthma for longer than 6 months
- Can you complete daily measurements at home for the next 6 months
- Have you needed to use oral steroids for worsening asthma symptoms
- Lung Gas Analyser (LGA) - An investigation into new measures of lung function. The assessment of lung function in patients with known or suspected lung disease is currently based upon measurements of how the lung is working as a whole, for example by measuring the speed of gas flow through the larger airways. However, many important lung problems affect only parts of the lung, and these so-called regional problems are very difficult to detect with current breathing tests. The purpose of this study is to investigate a new type of breathing test, which provides information about the regional variation of function within the lung. This is achieved though very accurate measurements of gas flow into and out of the lungs. These measurements are used by a mathematical model of the lung to estimate the variability of blood flow and gas flow within the lung, and to assess how well blood flow matches to gas flow.
- CHINOOK - A Phase 4, Multicenter, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Benralizumab on Structural and Lung Function Changes in Severe Eosinophilic Asthmatics
- HAMS - A prospective observational study using home monitoring devices for patients with asthma
- OPTIMAN - The use of exhaled nitric oxide to manage asthma in primary care. The OPTIMAN study is designed to demonstrate how we can use a chemical that is measurable in the breath to better give treatments for asthma. Asthma is a huge problem in the United Kingdom, and it has been demonstrated that people who have asthma find it hard to know how much treatment to take. If they do not take the right amount of treatment, usually in the form of inhaled anti-inflammation medication, then they have an increased risk of symptoms and even possibly asthma attacks. By measuring the levels of nitric oxide (FeNO) in the breath we are able to adjust the doses of treatment and thus improve levels of control. The OPTIMAN study aims to do this for both those who have already been diagnosed and treated for asthma and for those who are coming to see their GP for the very first time with symptoms of asthma. We aim to get the diagnosis of asthma correct and then using FeNO optimise the drug treatment.
If you are interested in taking part please do not hesitate to contact one of our research nurses on 01865 227242.
Ongoing trials (Recruitment finished):
- CASCADE - A Phase 2, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Tezepelumab on Airway Inflammation in Adults with Inadequately Controlled Asthma on Inhaled Corticosteroids and at least one additional asthma controller.
- ABRA STUDY- The use of Benralizumab, an interleukin-5 receptor-α monoclonal antibody as treatment of acute exacerbations of airways disease .
- CORAL STUDY - A 12-week exploratory study to characterise the relationship between changes in Inflammatory markers, lung function, symptoms and reliever use in Chronic Obstructive Pulmonary Disease Patients.
- RESOLUTE - A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils
- BAYER COUGH STUDY - Study 20393, BAY 1817080 Randomized, double-blind, parallel group, Phase 2b dose-finding, efficacy and safety study of 12-week twice daily oral administration of BAY 1817080 compared to placebo in the treatment of refractory and/or unexplained chronic cough (RUCC).
- SHIONOGI COUGH STUDY